114 citations
,
October 2006 in “Journal of the European Academy of Dermatology and Venereology” The new clobetasol propionate foam is effective and safe for treating alopecia areata.
June 2017 in “Journal of The American Academy of Dermatology” The new treatment was safe and may effectively treat male pattern hair loss.
4 citations
,
March 2016 in “Dermatologic Surgery” PRP treatment increased hair density, especially in men and younger patients with AGA.
Baricitinib helps regrow hair in teens with severe alopecia areata.
May 2025 in “The Journal of Rheumatology” Proactive physical therapy improved mobility, reduced fatigue, and pain in lupus patients.
3 citations
,
January 2011 in “Yearbook of Dermatology and Dermatologic Surgery”
44 citations
,
September 2015 in “Annals of Oncology” Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.
January 2025 in “Journal of Plastic Reconstructive & Aesthetic Surgery” Two L-PRP treatments improve hair density in mild to moderate alopecia.
1 citations
,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.
April 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.
February 2024 in “Frontiers in Cell and Developmental Biology” Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.
13 citations
,
June 2023 in “Frontiers in Pharmacology” Trastuzumab deruxtecan is effective for advanced breast cancer but has side effects like nausea and fatigue.
2 citations
,
December 2020 in “American Journal of Dermatological Research and Reviews” The combination therapy was effective and well-tolerated, especially in young patients.
1 citations
,
January 2000 in “PubMed” The treatment slightly increased hair growth and was safe for most women.
1 citations
,
December 2020 in “Medical lasers” The laser therapy device effectively increased hair growth in people with androgenetic alopecia.
14 citations
,
January 2001 in “Current Treatment Options in Oncology” Treat limited stage small cell lung cancer with chemotherapy and radiation, and consider preventive brain radiation for better survival chances.
April 2023 in “Journal of Investigative Dermatology” ALRN-6924 can protect hair follicles from chemotherapy damage by temporarily stopping cell division.
May 2019 in “Journal of clinical oncology” Topical calcitriol was safe and well-tolerated for potential hair loss prevention in chemotherapy patients.
1 citations
,
January 2024 in “Journal of Cutaneous and Aesthetic Surgery” Fractional CO2 laser with topical triamcinolone is more effective and safer for treating alopecia areata than intralesional triamcinolone.
63 citations
,
July 2024 in “Journal of the American Academy of Dermatology” Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.
September 2023 in “Journal of the American Academy of Dermatology” Oral difelikefalin significantly reduces itch in notalgia paresthetica.
January 1993 in “Journal of Dermatological Treatment” Most people who volunteered for a health study had medical issues, showing the need for careful screening before trials.
September 2023 in “Journal of the American Academy of Dermatology” November 2025 in “Journal of Clinical Medicine” Baricitinib significantly improved hair regrowth and quality of life in severe alopecia areata patients.
3 citations
,
October 2021 in “Clinical, Cosmetic and Investigational Dermatology” Setipiprant did not significantly improve hair growth in men with hair loss.
1 citations
,
October 2006 in “Urology” Alpha-blocker therapy may not be needed long-term when combined with finasteride for BPH.
June 2023 in “BMC Pharmacology and Toxicology” The trial will test if proxalutamide is safe and effective in reducing death in severe COVID-19 patients.
12 citations
,
March 2021 in “Patient Preference and Adherence” Patients and oncologists prioritize survival benefits, while payers focus on treatment costs.